|
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure.
|
1831369 |
1991 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
There was a significant step-up of the plasma BNP-LI level in the coronary sinus (CS) compared with that in the aortic root (Ao) and the difference between these BNP-LI levels, delta(CS-Ao)BNP, also increased with the severity of CHF.
|
1849149 |
1991 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure.
|
1831369 |
1991 |
|
Nephrosis
|
0.200 |
Biomarker
|
disease |
RGD |
These results indicate that in ADR-induced nephrosis, BNP secretion from the heart is increased.
|
8289999 |
1993 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In BIO14.6 and BIO53.58 strains at this age, ventricular BNP and ANP gene expressions are augmented, and the plasma BNP concentration is elevated to 136 and 108 fmol/ml, respectively, three times greater than the elevated plasma ANP concentration, which well mimics changes of the plasma BNP and ANP concentrations in human heart failure.
|
8083346 |
1994 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In BIO14.6 and BIO53.58 strains at this age, ventricular BNP and ANP gene expressions are augmented, and the plasma BNP concentration is elevated to 136 and 108 fmol/ml, respectively, three times greater than the elevated plasma ANP concentration, which well mimics changes of the plasma BNP and ANP concentrations in human heart failure.
|
8083346 |
1994 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cardiomyopathic hamsters, therefore, are useful models to investigate the implication of BNP in human cardiovascular diseases.
|
8083346 |
1994 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Human brain natriuretic peptide reduces blood pressure in normotensive and acute norepinephrine-induced hypertensive rabbits.
|
9194512 |
1997 |
|
Hypertensive disease
|
0.600 |
Therapeutic
|
group |
CTD_human |
Human brain natriuretic peptide reduces blood pressure in normotensive and acute norepinephrine-induced hypertensive rabbits.
|
9194512 |
1997 |
|
Hypotension
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Human brain natriuretic peptide reduces blood pressure in normotensive and acute norepinephrine-induced hypertensive rabbits.
|
9194512 |
1997 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
These results show that the pressure overload-induced activation of BNP gene expression differs between atrial and ventricular myocytes in the dTGR model of experimental hypertension.
|
10803492 |
1999 |
|
Atrial Fibrillation
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Persistent AF was associated with higher mRNA expression of pro-BNP (+66%, P = 0.04, in patients without valvular disease, and +69%, P < 0.01, in patients with valvular disease) and lower mRNA expression of NPR-A (-58%, P = 0.02, in patients without valvular disease, and -62 %, P < 0.01, in patients with valvular disease).
|
10376920 |
1999 |
|
Paroxysmal atrial fibrillation
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates that persistent, but not paroxysmal, AF induces alterations in gene expression of pro-BNP and NPR-A on the atrial level.
|
10376920 |
1999 |
|
Valvular disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Persistent AF was associated with higher mRNA expression of pro-BNP (+66%, P = 0.04, in patients without valvular disease, and +69%, P < 0.01, in patients with valvular disease) and lower mRNA expression of NPR-A (-58%, P = 0.02, in patients without valvular disease, and -62 %, P < 0.01, in patients with valvular disease).
|
10376920 |
1999 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Congestive heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Heart Diseases
|
0.560 |
Biomarker
|
group |
RGD |
Opposite regulation of brain and C-type natriuretic peptides in the streptozotocin-diabetic cardiopathy.
|
10828832 |
2000 |
|
Left-Sided Heart Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Left-Sided Heart Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Heart Failure, Right-Sided
|
0.300 |
Biomarker
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Heart Failure, Right-Sided
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |